Cargando…

Pre-Erythrocytic Vaccines against Malaria

Malaria, caused by the protozoan Plasmodium, is a devastating disease with over 200 million new cases reported globally every year. Although immunization is arguably the best strategy to eliminate malaria, despite decades of research in this area we do not have an effective, clinically approved anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques-da-Silva, Camila, Peissig, Kristen, Kurup, Samarchith P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565498/
https://www.ncbi.nlm.nih.gov/pubmed/32708179
http://dx.doi.org/10.3390/vaccines8030400
_version_ 1783595946168287232
author Marques-da-Silva, Camila
Peissig, Kristen
Kurup, Samarchith P.
author_facet Marques-da-Silva, Camila
Peissig, Kristen
Kurup, Samarchith P.
author_sort Marques-da-Silva, Camila
collection PubMed
description Malaria, caused by the protozoan Plasmodium, is a devastating disease with over 200 million new cases reported globally every year. Although immunization is arguably the best strategy to eliminate malaria, despite decades of research in this area we do not have an effective, clinically approved antimalarial vaccine. The current impetus in the field is to develop vaccines directed at the pre-erythrocytic developmental stages of Plasmodium, utilizing novel vaccination platforms. We here review the most promising pre-erythrocytic stage antimalarial vaccine candidates.
format Online
Article
Text
id pubmed-7565498
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75654982020-10-26 Pre-Erythrocytic Vaccines against Malaria Marques-da-Silva, Camila Peissig, Kristen Kurup, Samarchith P. Vaccines (Basel) Review Malaria, caused by the protozoan Plasmodium, is a devastating disease with over 200 million new cases reported globally every year. Although immunization is arguably the best strategy to eliminate malaria, despite decades of research in this area we do not have an effective, clinically approved antimalarial vaccine. The current impetus in the field is to develop vaccines directed at the pre-erythrocytic developmental stages of Plasmodium, utilizing novel vaccination platforms. We here review the most promising pre-erythrocytic stage antimalarial vaccine candidates. MDPI 2020-07-21 /pmc/articles/PMC7565498/ /pubmed/32708179 http://dx.doi.org/10.3390/vaccines8030400 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Marques-da-Silva, Camila
Peissig, Kristen
Kurup, Samarchith P.
Pre-Erythrocytic Vaccines against Malaria
title Pre-Erythrocytic Vaccines against Malaria
title_full Pre-Erythrocytic Vaccines against Malaria
title_fullStr Pre-Erythrocytic Vaccines against Malaria
title_full_unstemmed Pre-Erythrocytic Vaccines against Malaria
title_short Pre-Erythrocytic Vaccines against Malaria
title_sort pre-erythrocytic vaccines against malaria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565498/
https://www.ncbi.nlm.nih.gov/pubmed/32708179
http://dx.doi.org/10.3390/vaccines8030400
work_keys_str_mv AT marquesdasilvacamila preerythrocyticvaccinesagainstmalaria
AT peissigkristen preerythrocyticvaccinesagainstmalaria
AT kurupsamarchithp preerythrocyticvaccinesagainstmalaria